Share This 
Dr. Michael Will Be Responsible for Global Operations within BioAgilytix’s U.S. Headquarters and Recently Acquired European Laboratory, IPM Biotech
SEPTEMBER 23, 2016—Durham, NC—BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, has announcedthat Senior Vice President of Bioanalytical Operations Steven Michael, Ph.D. has been appointed Chief Operating Officer, a new position within BioAgilytix. Dr. Michael will continue to report to Jim Datin, CEO of BioAgilytix.
“Steve is a seasoned and trusted leader who consistently delivers results. His impressive background and former leadership role here at BioAgilytix make him uniquely qualified to drive strategic prioritization and accountability within our organization, with a strong focus on operational excellence,” said Jim Datin, Chief Executive Officer of BioAgilytix. “I have tremendous confidence in Steve’s ability to align BioAgilytix’s scientific excellence and customer focus with industry-leading operational practices. His leadership will help us continue to grow as one of the most advanced global laboratories for large molecule bioanalysis, while still delivering exceptional scientific results for our customers.”
Dr. Michael is an accomplished executive with over 20 years of experience leading successful teams in the Biotechnology and Pharmaceutical industries for companies focused on research and development. Prior to joining BioAgilytix, he held leadership roles at Covance and Pfizer Global Research and Development. His pharmaceutical industry experience includes drug discovery, drug development, and research technology with a focus on bioanalytical research, translational research, biomarkers, and leadership development.
“It has been an exciting couple of years at BioAgilytix with our exceptional growth rate, acquisition of IPM Biotech, and the significant expansion of our labs to better support our global customers,” said Dr. Michael. “I look forward to continuing to partner with our clients to drive their drug development projects with our world-class science, industry-leading operational processes and the extensive selection of platforms available at our global laboratories.”
Dr. Michael is a member of the American Society of Mass Spectrometry and the American Association of Pharmaceutical Scientists and has been published in various scientific publications, including Analytical Chemistry, Journal of Pharmaceutical and Biomedical Analysis, and International Journal of Mass Spectrometry and Ion Process. He received his doctorate in analytical chemistry from the University of Michigan.
###
Media Contact:
Jennifer Absher
Communications Specialist
[email protected]
